Cliff Asness's NBIX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 3.27 M shares of Neurocrine Biosciences, Inc. (NBIX) worth $462.65 M, representing 0.24% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in NBIX, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 1.26 M shares. Largest reduction occurred in Q1 2025, reducing 822,261 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Neurocrine Biosciences (NBIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Neurocrine Biosciences (NBIX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +498,058 | Add 17.96% | 3.27 M | $141.41 |
| Q3 2025 | +1.26 M | Add 83.68% | 2.77 M | $140.04 |
| Q2 2025 | +435,385 | Add 40.51% | 1.51 M | $125.69 |
| Q1 2025 | -822,261 | Reduce 43.35% | 1.07 M | $110.60 |
| Q4 2024 | +53,610 | Add 2.91% | 1.9 M | $136.50 |
| Q3 2024 | +620,226 | Add 50.71% | 1.84 M | $115.12 |
| Q2 2024 | +228,444 | Add 22.97% | 1.22 M | $136.51 |
| Q1 2024 | +255,759 | Add 34.62% | 994,611 | $137.92 |
| Q4 2023 | +364,890 | Add 97.57% | 738,852 | $131.52 |
| Q3 2023 | +16,264 | Add 4.55% | 373,962 | $112.50 |
| Q2 2023 | +126,624 | Add 54.80% | 357,698 | $94.30 |
| Q1 2023 | +124,539 | Add 116.90% | 231,074 | $98.88 |
| Q4 2022 | -7,068 | Reduce 6.22% | 106,535 | $119.09 |
| Q3 2022 | +81,596 | Add 254.93% | 113,603 | $104.45 |
| Q2 2022 | -40,742 | Reduce 56.00% | 32,007 | $96.76 |
| Q1 2022 | -27,772 | Reduce 27.63% | 72,749 | $93.33 |
| Q4 2021 | +52,958 | Add 111.34% | 100,521 | $85.14 |
| Q3 2021 | +7,052 | Add 17.41% | 47,563 | $95.39 |
| Q2 2021 | -1,580 | Reduce 3.75% | 40,511 | $96.47 |
| Q1 2021 | +30,775 | Add 271.96% | 42,091 | $97.08 |
| Q4 2020 | -37,808 | Reduce 76.96% | 11,316 | $93.76 |
| Q3 2020 | +957 | Add 1.99% | 49,124 | $96.16 |
| Q2 2020 | +14,097 | Add 41.38% | 48,167 | $121.99 |
| Q1 2020 | +9,302 | Add 37.56% | 34,070 | $86.56 |
| Q4 2019 | +13,257 | Add 115.17% | 24,768 | $107.15 |
| Q3 2019 | +1,192 | Add 11.55% | 11,511 | $89.74 |
| Q2 2019 | -51,329 | Reduce 83.26% | 10,319 | $82.37 |
| Q1 2019 | -57,876 | Reduce 48.42% | 61,648 | $88.10 |
| Q4 2018 | +53,487 | Add 81.00% | 119,524 | $71.41 |
| Q3 2018 | +38,582 | Add 140.53% | 66,037 | $122.95 |
| Q2 2018 | +11,732 | Add 74.62% | 27,455 | $98.23 |
| Q1 2018 | +15,723 | New Buy | 15,723 | $82.94 |
| Q2 2017 | -78,622 | Sold Out | 0 | $0.00 |
| Q1 2017 | -69,075 | Reduce 46.77% | 78,622 | $43.30 |
| Q4 2016 | -57,577 | Reduce 28.05% | 147,697 | $38.70 |
| Q3 2016 | +180,167 | Add 717.60% | 205,274 | $50.64 |
| Q2 2016 | -4,069 | Reduce 13.95% | 25,107 | $45.45 |
| Q1 2016 | -43,670 | Reduce 59.95% | 29,176 | $39.55 |
| Q4 2015 | -61,128 | Reduce 45.63% | 72,846 | $56.57 |
| Q3 2015 | -48,159 | Reduce 26.44% | 133,974 | $39.79 |
| Q2 2015 | +67,733 | Add 59.21% | 182,133 | $47.76 |
| Q1 2015 | +51,200 | Add 81.01% | 114,400 | $39.71 |
| Q4 2014 | -8,400 | Reduce 11.73% | 63,200 | $22.34 |
| Q3 2014 | -122,400 | Reduce 63.09% | 71,600 | $15.67 |
| Q2 2014 | -260,964 | Reduce 57.36% | 194,000 | $14.84 |
| Q1 2014 | +90,164 | Add 24.72% | 454,964 | $16.10 |
| Q4 2013 | +41,700 | Add 12.91% | 364,800 | $9.34 |
| Q3 2013 | +135,700 | Add 72.41% | 323,100 | $11.32 |
| Q2 2013 | +187,400 | Add 0.00% | 187,400 | $13.38 |
| Q4 2012 | +186,600 | Add 0.00% | 186,600 | $7.48 |
Cliff Asness's Neurocrine Biosciences Investment FAQs
Cliff Asness first purchased Neurocrine Biosciences, Inc. (NBIX) in Q4 2012, acquiring 186,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Neurocrine Biosciences, Inc. (NBIX) for 51 quarters since Q4 2012.
Cliff Asness's largest addition to Neurocrine Biosciences, Inc. (NBIX) was in Q3 2025, adding 2,773,648 shares worth $388.44 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 3,271,706 shares of Neurocrine Biosciences, Inc. (NBIX), valued at approximately $462.65 M.
As of the Q4 2025 filing, Neurocrine Biosciences, Inc. (NBIX) represents approximately 0.24% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Neurocrine Biosciences, Inc. (NBIX) was 3,271,706 shares, as reported at the end of Q4 2025.